--- title: "Gilead sells senior notes due 2028 through 2034 in public offering" url: "https://aibio.space/news/gilead-sells-senior-notes-due-2028-through-2034-public-offering/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-05-14" section: "Debt Financing" tickers: "NASDAQ:GILD" source: "https://www.sec.gov/Archives/edgar/data/882095/000110465926064518/tm2615045d1_8k.htm" summary: "Gilead sold four series of senior notes due 2028 through 2034 in a public offering, with coupons from 4.250% to 4.900%. Barclays, BofA Securities and Citig" --- By the aibio.space news desk. Sources - [SEC EDGAR](https://www.sec.gov/Archives/edgar/data/882095/000110465926064518/tm2615045d1_8k.htm) [GILD](https://aibio.space/companies/gilead-sciences/) 2026-05-14 # Gilead sells senior notes due 2028 through 2034 in public offering Tickers [GILD](https://aibio.space/companies/gilead-sciences/) Gilead sold four series of senior notes due 2028 through 2034 in a public offering, with coupons from 4.250% to 4.900%. Barclays, BofA Securities and Citigroup Global Markets are the representatives of the underwriters. ## Key facts - **Company**: Gilead Sciences, Inc. (NASDAQ: GILD) - **News type**: Debt Financing - **Primary source**: [SEC EDGAR](https://www.sec.gov/Archives/edgar/data/882095/000110465926064518/tm2615045d1_8k.htm) *A red price chart on a screen. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The offering Gilead Sciences, Inc. entered into an underwriting agreement on May 14, 2026 with Barclays Capital Inc., BofA Securities, Inc. and Citigroup Global Markets Inc., as representatives of the several underwriters listed in its schedule. The notes were sold in a public offering under the company's effective shelf registration statement on Form S-3, File No. 333-273745. Sidley Austin LLP gave an opinion on the validity of the notes. The 8-K names no other placement agent or financial advisor. The company issued four series. The 4.250% Senior Notes due 2028 total $500,000,000. The 4.400% Senior Notes due 2029 total $1,000,000,000. The 4.600% Senior Notes due 2031 total $1,000,000,000, and the 4.900% Senior Notes due 2034 total $500,000,000. Each series pays interest semi-annually, and the company may redeem some or all of the notes at the redemption prices set out in the form of each note. Gilead says it intends to use the net proceeds for general corporate purposes, which may include funding for acquisitions, investments, strategic transactions or other business opportunities. The 8-K does not tie the proceeds to any named transaction. ## The indenture The notes were issued under a base indenture dated March 30, 2011, with Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee. The Eleventh Supplemental Indenture, dated May 20, 2026, covers the four series. The 8-K says the base indenture and the supplemental indenture restrict the company's ability, and that of certain subsidiaries, to create or incur secured debt and to enter into sale and leaseback transactions. They also restrict the company from consolidating, merging or transferring all or substantially all of its assets and those of its subsidiaries. The company must offer to repurchase the notes after certain change-of-control events. The 8-K describes no limit on further unsecured borrowing. ## The company's financial position The 10-K, filed February 24, 2026, reports net income of $8.51 billion for 2025, against $480.0 million for 2024. Cash provided by operations was $10.02 billion in 2025, against $10.83 billion in 2024. The 10-K describes two stock repurchase programs. A $5.0 billion program was authorized in the first quarter of 2020, and repurchases under it started in December 2022. A $6.0 billion program was authorized in the third quarter of 2025 and will start once the 2020 program is complete. In the fourth quarter of 2025 the company repurchased 2,456 thousand shares at an average price of $119.17. Authority remaining at December 31, 2025 was $6,802 million. The new debt comes while both buyback authorizations remain in place. Both programs have no fixed expiration, do not obligate the company to repurchase any number of shares, and may be amended, suspended or discontinued at any time. The 8-K does not say how the notes relate to the repurchases. ## The company and what comes next Gilead describes itself as a biopharmaceutical company that has pursued breakthroughs in medicine for more than three decades, committed to advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. Its common stock trades on the Nasdaq Global Select Market under the symbol GILD, and the company paid quarterly dividends in 2025 and 2024. For significant pending legal proceedings, the 10-K refers readers to Note 12 of its consolidated financial statements. The 8-K, signed by Executive Vice President and Chief Financial Officer Andrew D. Dickinson, says interest on the four series runs until May 20 of 2028, 2029, 2031 and 2034, respectively. It sets no timetable for using the proceeds. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story GILD Gilead Sciences, Inc. NASDAQ ยท United States Open the desk ## More in Debt Financing Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 Debt Financing ### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/) Oct 30, 2026 Debt Financing ### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/) Oct 29, 2026 --- Source page: https://aibio.space/news/gilead-sells-senior-notes-due-2028-through-2034-public-offering/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Gilead sells senior notes due 2028 through 2034 in public offering", 2026-05-14, https://aibio.space/news/gilead-sells-senior-notes-due-2028-through-2034-public-offering/